News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|April 11, 2025

Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

Author(s)David Cotter, MD, PhD

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.

Episodes in this series

EP. 1 Limitations and Challenges in Skin Cancer Staging Systems

EP. 1 Limitations and Challenges in Skin Cancer Staging Systems

EP. 2 Utility of Molecular Testing in Skin Cancer Risk Assessment

EP. 2 Utility of Molecular Testing in Skin Cancer Risk Assessment

EP. 3 Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP. 3 Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP. 4 Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP. 4 Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP. 5 De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP. 5 De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP. 6 Key Takeaways on GEP Testing in Melanoma and SCC

EP. 6 Key Takeaways on GEP Testing in Melanoma and SCC

EP. 7 Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

EP. 7 Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

EP. 8 Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma

EP. 8 Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma

Video content above is prompted by the following:

Does the 31-GEP risk classification change your treatment guidelines?
How would you approach surveillance and follow-up with this patient after knowing their GEP risk level?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Therapy Gaps in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Counseling Caregivers in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Escalating to Systemic Therapies in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Treatment Adherence in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 7th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Transformative Advances This Year and Beyond

FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol

Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control

"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

© 2025 MJH Life Sciences^®

All rights reserved.